Dottikon ES Holding AG Logo

Dottikon ES Holding AG

Exclusive synthesis of APIs & fine chemicals via hazardous reactions for pharma/biotech industries.

DESN | SW

Overview

Corporate Details

ISIN(s):
CH0582581713
LEI:
50670064H782SV8G2Z44
Country:
Switzerland
Address:
Hembrunnstrasse 17, 5605 Dottikon
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dottikon ES Holding AG specializes in the exclusive synthesis of fine chemicals, manufacturing high-quality performance chemicals, intermediates, and active pharmaceutical ingredients (APIs). Serving the global chemical, biotech, and pharmaceutical industries, the company's core expertise lies in hazardous reactions, leveraging over 110 years of experience. Dottikon provides comprehensive services from research and development, including route-finding and process development, to multi-ton cGMP-compliant production. All operations are managed from a single strategic site, with quality management systems approved by the FDA and Swissmedic.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dottikon ES Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Dottikon ES Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-18 N/A Executive member Sell None 19,500,000.00 CHF
2023-07-24 N/A Executive member Sell None 72,600.00 CHF
2023-06-15 N/A Executive member Sell None 85,872,280.00 CHF
2023-06-15 N/A Non-Executive member Buy None 26,000.00 CHF
2023-06-01 N/A Non-Executive member Buy None 30,240.00 CHF

Peer Companies

Company Country Ticker View
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea 054180
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan 2207
Merck KGaA Logo
A science & tech firm in healthcare, life science, and electronics, advancing human progress.
United States of America 6MK

Talk to a Data Expert

Have a question? We'll get back to you promptly.